Good afternoon. My name is Christie, and I will be your conference operator today. At this time, I would like to welcome everyone to the WhiteHorse Financial Third Quarter 2020 Earnings Conference Call. Our hosts for today's call are Stuart Aronson, Chief Executive Officer; and Joyson Thomas, Chief Financial Officer. Today's call is being recorded and will be available for replay beginning at 5:00 P.M. Eastern Standard Time. The replay dial-in number is 404-537-3406, and the pin number is 4571047. At this time, all participants have been placed in a listen-only mode and the floor will be opened for questions following the presentation. [Operator Instructions] It is now my pleasure to turn the floor over to Sean Silva of Prosek Partners. Please go ahead.

Thank you, Christie, and thank you, everyone, for joining us today to discuss WhiteHorse Finance's Third Quarter 2020 Earnings Results. Before we begin, I would like to remind everyone that certain statements, which are not based on historical facts made during this call, including any statements related to financial guidance, may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Because these forward-looking statements involve known and unknown risks and uncertainties, these are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. WhiteHorse Finance assumes no obligation or responsibility to update any forward-looking statements. Today's speakers may refer to material from the WhiteHorse Finance third quarter 2020 earnings presentation, which was posted to our website this morning. With that, allow me to introduce Whitehorse Finance's CEO, Stuart Aronson. Stuart, you may begin.

Thank you, Sean. Good afternoon, everybody, and thank you for joining us today. I hope you and your families continue to be safe and healthy as we navigate the unprecedented times, and our thoughts remain with all of our stakeholders, included the dedicated employees across WhiteHorse and our H.I.G. family. We would also like to express our continued gratitude to all the health care and other frontline and essential workers, and we continue to send our sincere condolences to those families who have lost loved ones. As you're aware, we issued our press release this morning prior to market open, and I hope you've had a chance to review our results, which are also available on our website. I'm going to start by addressing our third quarter results and market conditions and Joyson Thomas, our Chief Financial Officer, will then discuss our performance in more detail, after which we will open the floor for questions. We're pleased to report a very strong third quarter with virtually every key metric trending positively. During the quarter, we earned our dividend. We increased our NAV. We had strong asset deployments. We reduced our non-accruals and we currently have the strongest pipeline in our history. I'll now provide more details on all of this. The NAV increased by 4.8% to $15.31 in Q3 compared to $14.61 in Q2. Q3 NAV eclipsed our pre-COVID level NAV of $15.23 at the end 2019 and is also in excess of our 2012 IPO price of $15 a share. Core NII, after adjusting for a $1.9 million capital gains incentive fee accrual was $7.8 million or $0.38 per share, compared to $5.42 million or $0.255 per share in Q2, comfortably covering our quarterly dividend. Our $1.9 million capital gains incentive fee accrual was the result of the $15.7…

Thank you, Stuart, and thank you all for joining today's call. During the third quarter, we recorded GAAP net investment income of $5.9 million or $0.289 per share. This compares to $5.2 million or $0.255 per share during Q2. Core NII was $7.8 million for the quarter or $0.38 per share, covering our dividend of $0.355 per share. During the quarter, we recorded net unrealized gains in our portfolio of $15.2 million, which were primarily driven by markups on fixed investments, aggregating to approximately $12.6 million and one markdown totaling $1.2 million. Our investment in the STRS JV increased to $50.4 million after the effects of transferring one position as well as from unrealized appreciation during the quarter. As of September 30, the JV's total portfolio comprised 18 issuers for the aggregate fair value of $162.6 million. Q3 fee income was approximately $0.7 million compared with $0.5 million in the prior quarter, driven by amendment and prepayment fees. After considering our net realized and unrealized gains, we reported a net increase in net assets resulting from operations of approximately $21.6 million. As of September 30, net asset value was approximately $314.6 million or $15.31 per share, which compares to $300.2 million or $14.61 per share in Q2, primarily driven by improved markups. As a result, our risk rating improved meaningfully during the quarter, whereas in Q2, 64.2% of our portfolio carried either one or two rating, that number in Q3 has increased to 76.5%. As a reminder, a one rating indicates that a company has seen its risk of loss reduced relative to initial expectations and a two rating indicates that the Company is performing according to our initial expectations. Turning to our balance sheet. We had cash resources of approximately $22.9 million at September 30, 2020, including $14.1 million…

Thank you. [Operator Instructions] And your first question is from Mike Smyth of B. Riley Securities.

So my first question is, if I look at Slide 16, it looks like one-rated companies jumped pretty good amount from 2.3% to just over 14%. It seems like kind of a big jump. I'm just wondering, is this just one large investment getting upgraded or several smaller ones? And if that's the case, is there any concentration of industries? I'm just wondering if you could provide any color here that would be helpful.

Joyson, do you have the list of deals that were moved up to a one handily available?

We do. Roughly speaking, it was 11 borrowers that saw improvements.

Got you. That's not. And is there any contention with industries or anything like that?

Just so you have clarity, we are seeing that outside of the directly COVID-impacted companies, the balance of the economic activity in our portfolio has been pretty strong, very strong. And so there are more companies, as Joyson has highlighted, that are performing at expected levels or above expected levels. But Joyson, go ahead, you were going to share some more detail?

Sure. I can share with you the names that saw improvements for the quarter, if that's helpful for you.

Yes, that would be helpful.

NMFC. All TV, Source Code, our position in Arcole, Alpha Media, Mills Fleet Farm, NNA Services, CHS Therapy, Opere, Vesco. Vero Parent -- excuse me, TrueBlue, not Vero Parent, and Lift brands.

Got you. That's helpful. And then another question would be, just given where the stock is trading and your confidence around credit, how do you think about balancing between potentially looking at buying back stock or putting capital to work in the investing environment?

Our general philosophy is that we are investing in very strong assets that are generating excellent returns for our investors. And we hope that with the continued earnings and a trend line where we hope to be able to earn our dividend on a quarterly basis from core net income that the shares will trade better. If the shares continue to trade very low, the Board does discuss and we can consider share buybacks, but that has not been determined to be the right thing to do so far.

Your next question is from Mickey Schleien of Ladenburg.

Stuart and Joyson. Stuart, a couple of high-level questions, if I can. First, broadly speaking, it seems like we can view credit today as it relates to sectors that are performing well despite the pandemic, and those are things like software and grocers. And then there are those that are struggling. Your portfolio is quite diversified by industry. So I'd like to understand how you view the potential for -- potential for more -- some deterioration of credit in the companies that are underperforming, if we were to see more stay-in-place orders as the pandemics curve gets worse now in the fall and going into the winter?

Mickey, it's good to hear from you. And it's a great question. Number one, we feel very fortunate that there's a limited portion of our portfolio that is COVID-affected. I also feel fortunate that in the case of all of the sponsor companies, who are in our portfolio that have been affected, the private equity firm owners have injected equity in to help these companies. Now as COVID has gone on longer than people originally hoped, and it looks like it will go on -- well, notwithstanding this morning's announcement, go on for at least another quarter or some of the companies that have gotten equity injections have gotten thin on liquidity. And we continue to work with the sponsors and the owners on those companies to help those companies get to the other side of COVID. If these companies get to the other side of COVID, frankly, all of them have the potential to return to part. These are otherwise fundamentally healthy companies that have been affected by the virus and the repercussions from it. That said, in the quarter, despite the fact that our NAV is above pre-COVID peak and above our original issuance, we did mark down four of our COVID-impacted assets because of the continued pressure. So we are trying to remain very realistic about the valuation on these assets, but it does help that all of these assets are first lien and it does help that the majority of these assets are sponsor-owned. And we hope to get to the other side of COVID and again, see even more NAV improvement as these companies return back to par if COVID ends and if the owners of these companies invest in the companies through the rest of the coped period. If they don't, and if we need to take over a company, we certainly have the ability to do that. We have restructuring experts in the Company. We have private equity professionals in the Company. And we do have the wherewithal to run a company and turn around the Company for our investors if the existing owners choose not to do that.

Well, I appreciate all that color, Stuart. That's really helpful. And on the flip side, there's a lot of yield-hungry private debt capital out there. And there are plenty of strong companies, as you've mentioned in your remarks, and they're getting a lot of attention. So how would you characterize the prepayment risk in your portfolio?

Three or four months ago, Mickey, I would have told you I wasn't going to see anything get prepaid. And yet, as I mentioned, Vesco, which is a credit that did an add-on acquisition during COVID, was performing very strongly. It was a non-COVID-affected company and was sold at a very good price. And as evidenced by our markup on the equity, we will make a gain on that investment that is a multiple of the original amount invested in the equity. We have seen several repayments. There are not many more that we expect between now and the end of the year based on the data we have. But if the economy does remain as strong as it is outside the COVID-affected areas based on our most recent portfolio review, we could see a number of current borrowers get sold in the first half of next year. So we do see there's a chance for some portfolio churn. That said, the markets are strong, our origination is strong, and we are going to strive to get to that 1.25 times leverage level of outstandings. And then especially on our non-sponsor companies, we have very strong prepayment protection. And to the extent that these loans are repaying within three years of them being made, we typically do get prepayment penalties. On the deals that paid off this quarter several of them did have prepayment penalties, including in Q4, Vesco had a prepayment penalty and Acumen, which paid off in the JV, also had a prepayment penalty.

I understand. That's interesting, Stuart. In terms of looking into next year, are there any new portfolio management themes that perhaps you're thinking about or going to start to employ now that we know there will be a new administration and the new President may have new policies for some important segments, such as health care or alternative energy. Is that impacting how you expect to allocate capital going forward?

We had already adjusted our investing parameters nine months ago based on the possibility of a change in administration. So anything that we've been doing in health care or infrastructure or any of the affected sectors has already been adapted to what we think the potential risks are of a democratic administration. So there's not really a change right now based on the fact that Biden has won because we've already incorporated all of that thinking into our risk downsides on our portfolios really since the beginning of the year.

How about opportunities? I mean, there's the opposite as well, right? Do you think that the change in administration is going to provide you some opportunities that you can take advantage of?

Mickey, from my perspective, investing in debt is about avoiding the downside. Our upside is we are in LIBOR 7, LIBOR 8 or LIBOR 9 and so only in our equity co-investments do we see that there is some upside? And obviously, if there is a stronger economy, the equity co-investments we've made are more likely to do well. And at the advice of, frankly, yourself and many analysts and shareholders, starting a couple of years ago, we were looking to increase the number of small equity investments we made in the BDC with a mindset that when they go well, we make two, three, four, five times our money like we did on Vesco and where we do poorly based on the size of those investments, we only lose $1 million to $1.5 million, so $0.05 to $0.075 a share. So certainly, on the equity co-invest side, we see upside but that's a small piece of what we do overall, as you can see from our investment numbers.

I understand. My last question, Stuart, any comment you can make about the overhang in the stock from the affiliated shareholders just in the context that the equity markets have been strong. There's certainly a lot more clarity today in terms of the government. And now we're getting more clarity on, hopefully, the end of the pandemic. Any thoughts or comments you can share with us about resolving that issue?

The Bayside shares are, of course, a much, much lower concentration than they were a couple of years ago. And we have an ongoing focus to try to make sure that we have stability in that situation, but there's nothing beyond the fact that we are focused on it that I can share at this time, Mickey.

Thank you. Your next question is from Robert Dodd of Raymond James.

So if I can go back to your prepared remarks real quick for AG Kings. Correct me, if I'm wrong here. I that you recognized $2.9 million of income and interest income on the first lien, can you -- A, tell me if I'm accurate at that? And B, given that asset that particular line loan is marked below cost? And on nonaccrual, can you tell us why you decided to take that into income instead of applying it all along with the bits that you did to the cost basis this quarter?

Joyson, can I pass you that question?

Sure, absolutely. Robert, so if you think about our position in Kings, a portion of the last out loan did convert into that super priority dip. So the way to think about the $2.9 million in interest payments, approximately $2.1 million of that was received prior to the bankruptcy filing as excess cash that we accounted for as interest income of the previously written-off interest that we had, again, previously accrued. That's in connection then with about $3.5 million that we also received allocated to the portion of our last-out debt that we had purchased in the prior quarter as a secondary purchase, that was accounted for as a reduction of our cost basis.

Got it.

Then...

Go ahead.

No, I'm sorry. So then post the pre-petition filing, we received about another $800,000 amongst both the super priority dip and that last-out term loan as interest payments.

Got it, got it. Understood. Thank you. Just then looking at the pipeline, obviously closed a number of deals in Q3, yes, a really strong pipeline, it looks like, for Q4. Can you give us any color on how you're evaluating? Obviously, you have perhaps a greater exposure and pipeline access to non-sponsored deals than most other BDCs in contrast to just doing sensor deals. How are you evaluating the risks between the two right now, given that things, obviously non-sponsored that isn't the potential -- reduced potential for equity injections if there is trouble, and the outlook is still quite uncertain, even with this morning's news. So how are you evaluating sponsored versus non-sponsored in the environment right now?

Sure. So Robert, we've always made the case that the non-sponsored deals that we do are done on much more conservative terms with much more conservative documents and much tighter covenants than our sponsor deals. And we've put forth to the marketplace that in our experience, both as a firm and as individuals that non-sponsored lending when it's done at much, much lower leverage results in strong performance through market disruptions. As we've hit COVID and we've had a very severe market disruption, the only asset that is in our high COVID-impact bucket that is non-sponsor is Grupo HIMA. And as you could tell from the mark on that asset, Grupo HIMA had issues prior to COVID. So what's really happened is our non-sponsor book on average has performed more strongly than our sponsor book because the starting leverage is so much lower that even if these companies have experienced 10%, 20%, 30%, 40% decreases in EBITDA, the leverage is still modest. The companies are able to service their debt load. And while we've had covenant violations, we've taken fees or increased the rates on these deals. So our experience is that in the midst of a crisis, the non-sponsor loans are performing extremely well, better on average than the sponsor loans are. And our non-sponsor pipeline continues to be much less competitive than our sponsor pipeline, especially because the banks for, in many cases, have been sidelined. And so we are working on, as I mentioned in my prepared remarks, we're working on non-sponsored deals that are 3 to 3.5 times leverage that have pricing that ranges from L 8.50 to L 12. And some of these deals, the leverage is so low that if the banks were operating normally, these might be bank loans at LIBOR 3.50. But on all of these deals, we get call protection. And so if the banks do get back to normal in six months and we get repaid, we will get very significant call penalties if these loans go away from us. So we love our non-sponsor pipeline and are aggressively trying to put more of those loans on the books if the credits are good and if the risk return is appropriate.

Got it. I really appreciate that color, and I know you didn't get a double-digit yield on a first lien, you're doing okay. One final one, if I can. And you got Grupo HIMA, I mean, yes, it's had problems historically because it kept getting hit by hurricanes. For this quarter, to your point, you put it into the high category. What can you tell us about why has that -- why is it high this quarter, but it wasn't before? Has something changed in the patient mix, or for lack of a better term, that just necessitates the switch this quarter?

COVID got worse in Puerto Rico. And the impact on the hospitals was also more severe. So the other thing that was going on is, if you go back to last quarter, the government was providing active support to hospitals across the country. And as we know, the government support of everything and everybody has been stalled. It is our hope, and it's the hope of the owners of Grupo HIMA that in the face of the COVID disruption, that the government will continue to support hospitals through the cash flow disruptions that they're having, but there is no certainty of that happening at this point. And therefore, we found it prudent to mark that asset down more just because there is uncertainty looking forward as to what the government will do and when the cash flows at these hospitals will normalize from typical elective procedures being at a pre-COVID pace.

[Operator Instructions] And your next question is from Rick Shane of JPMorgan.

And first of all, I do appreciate the disclosure is excellent and very helpful. I'm not sure if I missed this, but was there a reversal of interest income as nonaccruals came off? Is there anything that flows through the interest income line that we should think of as sort of non-recurring?

Rick, there wouldn't have been anything this quarter given that we didn't put any additional credits on nonaccrual. But in prior quarters, there could have been instances where we would have reversed out amounts that had been on the balance sheet and not received yet.

I actually meant the question in the opposite with the nonaccruals coming down, was there anything that added to interest income this quarter that was added back?

AG Kings, the amount that I had mentioned on AG Kings part of. I'm sorry, AG Kings -- a piece of that asset is now been rolled up in the super priority dip, and we are collecting ongoing cash interest on that. But there was more AG Kings interest that was accrued, that was paid that had originally been written off. And Joyson confirm for me, that's $2.1 million plus $0.8 million were the two pieces that were both pre-petition and post petition. Is that right?

That's correct.

Got it. Okay. That's helpful. And then, again, just love to sort of revisit the question of share repurchases. And I understand that it's a tricky issue in terms of liquidity, and there are some issues associated with that just in terms of investor -- investors wanting more float. But at the same time, shares are trading at a 30% discount to NAV. You pointed to some places within the portfolio where you think there's opportunity for accretion back towards cost. It strikes me in the array of investments that you have that it's a highly known vehicle that you'd be investing in and with a path to realization that seems to make a lot of sense, why not be a little bit more aggressive there?

Rick, all I can tell you is that we have had that conversation with the Board. The moment where it might have been most interesting to do it was as the stock market was going through a major correction, our shares traded to a much larger discount. But at that point in time, as we shared with all of you and with our shareholders, we were very focused on maintaining liquidity because lenders, including JP Morgan, were marking assets down out of both a reaction to what had happened in the marketplace and frankly, out of fear. And so we wanted to make sure that no matter how severe the downturn seemed to be that we would not create a liquidity problem for our shareholders, and we would not have a disruptionin the dividend. So when the shares were $7 or $8, we certainly have that conversation. Our hope is that as things normalize and we share good information with the market, if the shares will trade back to a much better level. If they don't, the Board will once again convene and decide as to whether it makes sense to use up the liquidity to repurchase shares in the marketplace.

No, I appreciate that. And again, we can all look back at sort of bottom tech some stocks and which we'd acted, but we also have to consider our own sentiment at that time and the responsibility that you guys need to maintain in terms of liquidity as well. So I appreciate that.

Thank you. Your next question is from Chris Kotowski of Oppenheimer.

Yes. I just hate to go back to it, but I want to make sure I understand the AG Kings' situation. And I guess going back to the earlier question about kind of how much catch-up interest there is. I mean -- so am I thinking about it correctly, if I say, okay, you took $2.9 million into income this quarter, kind of on a go-forward basis, if everything stays as it is, you just have the $14 million super priority secured loan, that's got an 11% coupon, so that would be about $400,000 a quarter. So kind of the extra interest income in this quarter was somewhere around $2.5 million. Am I thinking about that right?

Joyson, does that sound right to you?

Yes, Chris. So to clarify that point, I think that is the right way to look at it. We have the last out piece on nonaccrual. That said, while it's in bankruptcy, our expectation is that would be paid interest as well in addition to the super priority dip. So in, let's say, for Q4, our expectation is we would potentially recover and record additional amounts of interest relating not only again to the dip piece, but also that remaining last out.

Okay. All right. But yes, I mean, but the difference, delta versus just a priority piece, the dip piece is -- yes. Okay. And then I guess, I'm kind of curious just you are much more encouraging about loan demand and you experienced it sooner than most of the other BDCs recover. A lot of -- I mean, most of them had either flat or down loan volumes quarter-on-quarter. And I guess what do you attribute that? Is it your greater concentration in non-sponsor demand? Or you see or is it just better opportunities in general?

It's a couple of things, in our opinion. Number one, we didn't shut down. The -- I would tell you based on what I saw, 90% to 95% of the lenders shut down in March, April, May. And even though there were people who were claiming they were in business, they were putting forth offers of financing that were illogical, like no one could take them. So by not shutting down, we enhanced our position in the overall market. And we landed a couple of deals that were just super, super attractive. At the time, everybody was afraid, but in retrospect, they look like really good deals. And then we have a direct origination mechanism that is in local markets that allows us to find deals that are not coming through the syndicated bank chain. And we are finding deals that have, in some cases, literally no competition. And we're working on a deal -- well, working on several deals right now for companies that are sort of $10 million, $12 million of EBITDA that did not have banker intermediaries that we have sourced directly. One of them is levered three times. One of them has levered 3.5 times. Both of these companies are worth 7 times to 12 times EV. And we are commanding pricing that is reflective of the fact that we directly originated the deals. So our pipeline, what I heard from my compatriots in the marketplace is at the bottom-COVID Pipelines were down 80% to 95%. Our pipeline never fell more than 2%. And when I did our transaction review this morning, we had 136 deals in our pipeline. Now, of course, a very small fraction of those closed. But last year around the same time, I think it was around 107 deals or something like that. So this direct origination mechanism and having stayed in the marketplace has just positioned us very well. And it's allowed us to continue to have discipline. I mentioned it in my prepared remarks. But in the sponsored market, a lot of lenders have come back. They weren't lending for6 months, and so they're way, way behind budget. And so we see certain lenders doing things that look, frankly, pretty desperate. And we're just able to walk away from those situations. We don't need to chase. So it's a nice luxury to have. Again, a lot of mandated deals for the quarter, I can't be sure that any of them will close because we're in the midst of due diligence. But if we do close all of the mandated deals or even most of the mandated deals, we'll make solid strides toward getting to the target of 1.25% leverage and having a core asset base that drives the income levels up on our portfolio.

Thank you. Your next question is from Bryce Rowe of National Securities.

I wanted to ask a little bit more about the pipeline and kind of how it relates to the balance sheet leverage target. I mean, clearly, you're very encouraged by the pipeline and the potential for some growth here in the portfolio. So kind of with that in mind and then with the context of the new unsecured notes offering, I'm curious what -- how you think about capital structure should you hit that 1 25 target? I mean, do you want to continue to expand the unsecured notes as a percentage, as you work towards that 1 25? Or are you comfortable possibly taking down the balance of the credit facility and expanding it with the accordion?

Yes. It's a great question, Bryce. We continue to evaluate the situation based on the nature of the opportunity and pricing in the marketplace. Needless to say, we are able to borrow on a secured basis at a much lower rate than on an unsecured basis, even at the very attractive 5 3/8% that we just issued. And what we continue to do is look at downside scenarios to make sure that if you have a repeat of March, April, where, again, and hopefully, it won't be COVID, but things happen, we want to make sure in a downside scenario, we have tons of room before there's any disruption to the dividend to our investors. Again, we shared with investors during March, April, May period, we had successfully done. We did not run into liquidity problems. As you know, several other players in the marketplace did. And so we do that by a mix of secured, unsecured. We do that by minimizing the amount of revolver exposure that we have. And we would take on more unsecured if we felt the pricing was right as we move towards 1.25%, but we don't need to take on more unsecured. So it will really be an opportunistic decision as the deployment of the capital continues to occur.

Okay. That's helpful. And I would guess that relative to three or four months ago, to talk about getting to that 1 25, it seems like it could happen sooner now than it would have happened than you would have thought three or four months ago. Am I thinking about that correctly, given the pipeline discussion that we're having here?

We were absolutely delighted in August, September, October, to see the surge in deal activity that we saw. And no, we did not predict that three to six months ago. We thought, frankly, that deal activity would be very limited through the balance of the year, but it has not been. It's very strong, and you're hearing that from others as well, I'm sure. So the question becomes how many deals do you win? And I've shared with you how many mandated deals I have and hopefully, a good percentage of those closed. But beyond the mandated deals, as we get into quasi mid-November, there's more deal flow that could be mandated and frankly, could close by year-end, and if some of those things break our way or in the direction of our clients, we could make good progress towards getting to that 1.25.

Okay. Okay. That's great.

I could also -- just so you know, I should also mention that we don't keep all the assets directly on our balance sheet. We do use our JV. And the JV is also highly accretive to income as the junior capital in that JV returns double-digit returns. And any deals that are priced L 6.50 and below, which are generally in this market, senior secured very good credits do go into that JV.

Okay. Yes, that was going to kind of be my next line of questioning and trying to understand kind of what the pace of originations that the JV would be or at least the pace of your continued investments into it. So it sounds like you'll hit that $75 million over the next 6 to 12 months, perhaps?

We certainly could hit the full utilization over the next 6 to 12 months. And depending on what the economics look like at that moment, we could make a decision to increase the allocation into the JV, if that was accretive to our shareholders.

Okay. Okay. And then one kind of, I guess, modeling question. You talked about the Arcole getting restructured into equity. So you'll take a realized loss on the debt. And I'm curious, maybe, Joyson, you can help me with this. But what the equity investment -- what the size of the equity investment might look like as we see the fourth quarter financials?

So before I pass it to Joyson, let me just share with you that the underlying company performance at Arcole is very strong. The Company has not had any significant COVID effect. And we believe that there is potentially good equity upside in that asset over the period of time that we choose to own it. But in terms of how many dollars it turns out to be, Joyson, can you share that the numbers look like?

Yes. I think in regards to the accounting treatment, obviously, we haven't finalized the accounting for the Q4 transaction. But I think our preliminary thoughts are that it's a nontaxable transaction. And so we'll be rolling overall cost basis into the common equity shares. And so Stuart, my understanding is, I believe it's overall, we would have essentially 75% or represented 25% ownership through kind of common in any preferred units.

We have no further questions at this time. I will now turn the call back over to management for any additional or closing remarks.

Everyone, I appreciate the time you spent with us. If there are more things that come up, we always strive to be transparent. And I encourage you prior to our calls each quarter, if there are information flows that we can share with the marketplace and with you that are useful, please try to let us know that prior to the call so we can incorporate that into prepared remarks. But that's all we have. And again, I hope everyone does well through the rest of the COVID crisis. Thank you.

Thank you. This does conclude today's conference call. You may now disconnect.